STOCK MARKET BSE NSE

India May Take WTO Action Against EU Over Drug Clinical Trials - GVK

India may go to the World Trade Organisation (WTO) if the European Union does not reconsider a decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm\'s CEO said.

Published: 16th April 2015 10:11 AM  |   Last Updated: 16th April 2015 10:11 AM   |  A+A-

MUMBAI: India may go to the World Trade Organisation (WTO) if the European Union does not reconsider a decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said.

The European Medicines Agency (EMA) suspension became effective in January, a month after France, Germany, Belgium and Luxembourg suspended the sale of 25 generic drugs that were approved based on trials conducted by GVK Biosciences.

The privately-held company, part of India's infrastructure builder GVK Group, conducts clinical research for domestic and foreign drugmakers.

The regulatory actions were taken after the French watchdog inspected a GVK Biosciences manufacturing plant in southern India last year and found manipulation of data from electrocardiograms for at least five years.

The French regulator said at the time that suspensions were taken out of precaution and there was no reason to suggest the drugs were ineffective or harmful.

The drugs suspended by the EMA include those made by U.S. firms Mylan Inc and Abbott Laboratories, as well as large Indian companies such as Lupin Ltd and Dr Reddy's Laboratories.

After an appeal by the company, the Indian government set up a panel of experts last year to investigate the matter and found no manipulation, GVK Biosciences CEO Manni Kantipudi told Reuters.

An Indian government delegation visited the European authorities between February and March to ask for the suspension to be reconsidered, Kantipudi said.

If that does not happen, New Delhi is ready to take commercial and legal action, which could include action at the WTO, India's Commerce Secretary Rajeev Kher told local daily Hindu BusinessLine last week.

The commerce department did not respond to a request for comment by Reuters.

"There are some legal options, but we will see what comes out of these diplomatic talks and then we and the commerce ministry will decide on what to do," Kantipudi said.

In an email, EMA spokeswoman Rebecca Harding confirmed the meeting with the delegation of the Indian government regarding GVK Biosciences' clinical trials, and said a "re-examination procedure" is ongoing and is expected to be finalised in May 2015.

GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues. Several large Indian drugmakers have over the past two years faced U.S. and UK sanctions over issues ranging from data fabrication and manipulation, to sanitation.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp